Borthakur, G., Ofran, Y., Tallman, M. S., Foran, J., Uy, G. L., DiPersio, J. F., Showel, M. M., Shimoni, A., Nagler, A., Rowe, J. M., Altman, J. K., Abraham, M., Peled, A., Shaw, S., Bohana‐Kashtan, O., Sorani, E., Pereg, Y., Foley‐Comer, A., Oberkovitz, G., Lustig, T. M., Glicko‐Kabir, I., Aharon, A., Vainstein‐Haras, A., Kadosh, S. E., Samara, E., Al‐Rawi, A. N., Pemmaraju, N., Bueso‐Ramos, C., Cortes, J. E., & Andreeff, M. (2021). bL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study. Cancer, 127(8), 1246–1259. http://access.bl.uk/ark:/81055/vdc_100127487084.0x00003c